Zerviate is a drug owned by Harrow Eye Llc. It is protected by 6 US drug patents filed from 2017 to 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 09, 2033. Details of Zerviate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US9254286 (Pediatric) | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(7 years from now) | Active |
| US9254286 | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(6 years from now) | Active |
|
US8829005 (Pediatric) | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(4 years from now) | Active |
| US8829005 | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(4 years from now) | Active |
| US9993471 | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(4 years from now) | Active |
| US9750684 | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Zerviate's patents.
Latest Legal Activities on Zerviate's Patents
Given below is the list of recent legal activities going on the following patents of Zerviate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Aug, 2023 | US9254286 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8829005 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Nov, 2021 | US9993471 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Feb, 2021 | US9750684 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Jul, 2019 | US9254286 |
| Recordation of Patent Grant Mailed
Critical | 12 Jun, 2018 | US9993471 |
| Patent Issue Date Used in PTA Calculation
Critical | 12 Jun, 2018 | US9993471 |
| Email Notification
Critical | 24 May, 2018 | US9993471 |
| Issue Notification Mailed
Critical | 23 May, 2018 | US9993471 |
| Dispatch to FDC | 15 May, 2018 | US9993471 |
FDA has granted several exclusivities to Zerviate. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Zerviate, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Zerviate.
Exclusivity Information
Zerviate holds 2 exclusivities. All of its exclusivities have expired in 2020. Details of Zerviate's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
US patents provide insights into the exclusivity only within the United States, but
Zerviate is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zerviate's family patents as well as insights into
ongoing legal events
on those patents.
Zerviate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zerviate's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 09, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zerviate Generic API suppliers:
Cetirizine Hydrochloride is the generic name for the brand Zerviate. 47 different companies have already filed for the generic of Zerviate, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zerviate's generic
Alternative Brands for Zerviate
Zerviate which is used for providing relief from ocular itching associated with allergic conjunctivitis., has several other brand drugs in the same treatment category and using the same active ingredient (Cetirizine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alcon Labs Inc |
| |||
| Ocular Therapeutix |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Cetirizine Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Jdp |
| |||
| Kenvue Brands |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cetirizine Hydrochloride, Zerviate's active ingredient. Check the complete list of approved generic manufacturers for Zerviate
About Zerviate
Zerviate is a drug owned by Harrow Eye Llc. It is used for providing relief from ocular itching associated with allergic conjunctivitis. Zerviate uses Cetirizine Hydrochloride as an active ingredient. Zerviate was launched by Harrow Eye in 2017.
Approval Date:
Zerviate was approved by FDA for market use on 30 May, 2017.
Active Ingredient:
Zerviate uses Cetirizine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cetirizine Hydrochloride ingredient
Treatment:
Zerviate is used for providing relief from ocular itching associated with allergic conjunctivitis.
Dosage:
Zerviate is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.24% BASE | SOLUTION/DROPS | Prescription | OPHTHALMIC |